Racial disparities in prostate cancer: A molecular perspective

Frontiers in Bioscience - Landmark

Volumn 22, Issue 5, 2017, Pages 772-782

  Bhardwaj, Arun ^a   Srivastava, Sanjeev K ^a   Khan, Mohammad Aslam ^a   Prajapati, Vijay K ^a   Singh, Seema ^a,b   Carter, James E ^b   Singh, Ajay P ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Genetics; Growth factors; Inflammatory signaling; MiRNAs; Prostate cancer; Racial disparities

Indexed keywords

MICRORNA;

AFRICAN AMERICAN; CAUCASIAN; GENETIC EPIGENESIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HEALTH BEHAVIOR; HUMAN; INCIDENCE; MALE; MUTATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; SOCIOECONOMICS; UNITED STATES;

AFRICAN AMERICANS; EPIGENESIS, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HEALTH BEHAVIOR; HUMANS; INCIDENCE; MALE; MICRORNAS; MUTATION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 85010411796     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4515     Document Type: Article

References (65)

1. R.L. Siegel, K.D. Miller, A. Jemal: Cancer statistics, 2016. CA Cancer J. Clin. 66 7-30 (2016) DOI: 10.3322/caac.21332
2. P. Fernandez, M. Salie, T.D. du, A. van der Merwe: Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11. Prostate Cancer DOI: 10.1.155/2015/465184 (2015)
3. L.S. Lim, K. Sherin: Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am.J. Prev. Med. 34 164-170 (2008) DOI: 10.1016/j.amepre.2007.10.003.
4. M.R. Cooperberg: Re-examining racial disparities in prostate cancer outcomes. J. Clin. Oncol. 20;31 2979-2980 (2013)
5. S. Chhatre, M.S. Bruce, S.J. Sanford, R. Jayadevappa: Understanding the Racial and Ethnic Differences in Cost and Mortality Among Advanced Stage Prostate Cancer Patients (STROBE) Medicine (Baltimore) 94 e1353 (2015) DOI: 10.1097/MD.0000000000001353
6. R.M. Hoffman, F.D. Gilliland, J.W. Eley, L.C. Harlan, R.A. Stephenson, J.L. Stanford, P.C. Albertson, A.S. Hamilton, W.C. Hunt, A.L. Potosky: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J. Natl. Cancer Inst. 93 388-395 (2001) DOI: 10.1093/jnci/93.5.388
7. K.F. McGinley, K.J. Tay, J.W. Moul: Prostate cancer in men of African origin. Nat. Rev. Urol. 13 99-107 (2016) DOI: 10.1038/nrurol.2015.298
8. I.J. Powell, A. Bollig-Fischer: Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol. Endocrinol. 27 879-891 (2013) DOI: 10.1210/me.2013-1039
9. B. Shuch, M. Mikhail, J. Satagopan, P. Lee, H. Yee, C. Chang, C. Cordon-Cardo, S.S. Taneja, I. Osman: Racial disparity of epidermal growth factor receptor expression in prostate cancer. J. Clin. Oncol. 22 4725-4729 (2004) DOI: 10.1200/JCO.2004.06.134
10. A.B. Murphy, Y. Nyame, I.K. Martin, W.J. Catalona, C.M. Hollowell, R.B. Nadler, J.M. Kozlowski, K.T. Perry, A. Kajdacsy-Balla, R. Kittles: Vitamin D deficiency predicts prostate biopsy outcomes. Clin. Cancer Res. 20 2289-2299 (2014) DOI: 10.1158/1078-0432.CCR-13-3085
11. K. Batai, A.B. Murphy, L. Nonn, R.A. Kittles: Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Front Immunol. 7: 53 (2016) DOI: 10.3389/fimmu.2016.00053
12. M. Gacci, E. Baldi, L. Tamburrino, B. Detti, L. Livi, N.C. De, A. Tubaro, S. Gravas, M. Carini, S. Serni: Quality of Life and Sexual Health in the Aging of Prostate cancer Survivors. Int.J. Endocrinol DOI: 10.1.155/2014/470592 (2014).
13. E.M. Ledet, O. Sartor, W. Rayford, J.E. Bailey-Wilson, D.M. Mandal: Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana. Prostate. 72 938-947 (2012) DOI: 10.1002/pros.21496
14. J.T. Bensen, Z. Xu, G.J. Smith, J.L. Mohler, E.T. Fontham, J.A. Taylor: Genetic polymorphism and prostate cancer aggressiveness: a caseonly study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate. 73 11-22 (2013) DOI: 10.1002/pros.22532
15. L.T. Amundadottir, P. Sulem, J. Gudmundsson, A. Helgason, A. Baker, B.A. Agnarsson, A. Sigurdsson, K.R. Benediktsdottir, J.B. Cazier, J. Sainz, M. Jakobsdottir, J. Kostic, D.N. Magnusdottir, S. Ghosh, K. Agnarsson, B. Birgisdottir, R.L. Le, A. Olafsdottir, T. Blondal, M. Andresdottir, O.S. Gretarsdottir, J.T. Bergthorsson, D. Gudbjartsson, A. Gylfason, G. Thorleifsson, A. Manolescu, K. Kristjansson, G. Geirsson, H. Isaksson, J. Douglas, J.E. Johansson, K. Balter, F. Wiklund, J.E. Montie, X. Yu, B.K. Suarez, C. Ober, K.A. Cooney, H. Gronberg, W.J. Catalona, G.V. Einarsson, R.B. Barkardottir, J.R. Gulcher, A. Kong, U. Thorsteinsdottir, K. Stefansson: A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38 652-658 (2006) DOI: 10.1038/ng1808
16. C. Zeigler-Johnson, T. Friebel, A.H. Walker, Y. Wang, E. Spangler, S. Panossian, M. Patacsil, R. Aplenc, A.J. Wein, S.B. Malkowicz, T.R. Rebbeck: CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64 8461-8467 (2004) DOI: 10.1158/0008-5472.CAN-04-1651
17. C.M. Zeigler-Johnson, E. Spangler, M. Jalloh, S.M. Gueye, H. Rennert, T.R. Rebbeck: Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can.J. Urol. 15 3872-3882 (2008)
18. G. Casey, P.J. Neville, S.J. Plummer, Y. Xiang, L.M. Krumroy, E.A. Klein, W.J. Catalona, N. Nupponen, J.D. Carpten, J.M. Trent, R.H. Silverman, J.S. Witte: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 32 581-583 (2002) DOI: 10.1038/ng1021
19. J. Li, E. Mercer, X. Gou, Y.J. Lu: Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. Am.J. Cancer Res. 3 127-151 (2013)
20. P.A. Watson, V.K. Arora, C.L. Sawyers: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer. 15 701-711 (2015) DOI: 10.1038/nrc4016
21. J. Farrell, G. Petrovics, D.G. McLeod, S. Srivastava: Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int.J. Mol. Sci. 14 15510-15531 (2013) DOI: 10.3390/ijms140815510
22. E.M. Lange, A.V. Sarma, A. Ray, Y. Wang, L.A. Ho, S.A. Anderson, J.M. Cunningham, K.A. Cooney: The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J. Hum. Genet. 53 220-226 (2008) DOI: 10.1007/s10038-007-0240-4
23. G. Thomas, K.B. Jacobs, M. Yeager, P. Kraft, S. Wacholder, N. Orr, K. Yu, N. Chatterjee, R. Welch, A. Hutchinson, A. Crenshaw, G. Cancel-Tassin, B.J. Staats, Z. Wang, J. Gonzalez-Bosquet, J. Fang, X. Deng, S.I. Berndt, E.E. Calle, H.S. Feigelson, M.J. Thun, C. Rodriguez, D. Albanes, J. Virtamo, S. Weinstein, F.R. Schumacher, E. Giovannucci, W.C. Willett, O. Cussenot, A. Valeri, G.L. Andriole, E.D. Crawford, M. Tucker, D.S. Gerhard, J.F. Fraumeni, Jr., R. Hoover, R.B. Hayes, D.J. Hunter, S.J. Chanock: Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40 310-315 (2008) DOI: 10.1038/ng.91
24. B.L. Chang, E. Spangler, S. Gallagher, C.A. Haiman, B. Henderson, W. Isaacs, M.L. Benford, L.R. Kidd, K. Cooney, S. Strom, S.A. Ingles, M.C. Stern, R. Corral, A.D. Joshi, J. Xu, V.N. Giri, B. Rybicki, C. Neslund-Dudas, A.S. Kibel, I.M. Thompson, R.J. Leach, E.A. Ostrander, J.L. Stanford, J. Witte, G. Casey, R. Eeles, A.W. Hsing, S. Chanock, J.J. Hu, E.M. John, J. Park, K. Stefflova, C. Zeigler-Johnson, T.R. Rebbeck: Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol. Biomarkers Prev. 20 23-32 (2011) DOI: 10.1158/1055-9965.EPI-10-0698
25. R.A. Kittles, A.B. Baffoe-Bonnie, T.Y. Moses, C.M. Robbins, C. Ahaghotu, P. Huusko, C. Pettaway, S. Vijayakumar, J. Bennett, G. Hoke, T. Mason, S. Weinrich, J.M. Trent, F.S. Collins, S. Mousses, J. Bailey-Wilson, P. Furbert-Harris, G. Dunston, I.J. Powell, J.D. Carpten: A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J. Med. Genet. 43 507-511 (2006) DOI: 10.1136/jmg.2005.035790
26. S.M. Edwards, Z. Kote-Jarai, J. Meitz, R. Hamoudi, Q. Hope, P. Osin, R. Jackson, C. Southgate, R. Singh, A. Falconer, D.P. Dearnaley, A. Ardern-Jones, A. Murkin, A. Dowe, J. Kelly, S. Williams, R. Oram, M. Stevens, D.M. Teare, B.A. Ponder, S.A. Gayther, D.F. Easton, R.A. Eeles: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am.J. Hum. Genet. 72 1-12 (2003) DOI: 10.1086/345310
27. T.A. Scott, R. Arnold, J.A. Petros: Mitochondrial Cytochrome c Oxidase subunit 1 Sequence Variation in Prostate Cancer. Scientifica. Cairo.) 2012: 701810. 701810 (2012)
28. P.A. Jones, S.B. Baylin: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 415-428 (2002)
29. B. Kwabi-Addo, S. Wang, W. Chung, J. Jelinek, S.R. Patierno, B.D. Wang, R. Andrawis, N.H. Lee, V. Apprey, J.P. Issa, M. Ittmann: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin. Cancer Res. 16 3539-3547 (2010) DOI: 10.1158/1078-0432.CCR-09-3342
30. K. Woodson, R. Hayes, L. Wideroff, L. Villaruz, J. Tangrea: Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate. 55 199-205 (2003) DOI: 10.1002/pros.10236
31. K. Woodson, J. Hanson, J. Tangrea: A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 205 181-188 (2004) DOI: 10.1016/j.canlet.2003.11.027
32. H. Enokida, H. Shiina, S. Urakami, M. Igawa, T. Ogishima, D. Pookot, L.C. Li, Z.L. Tabatabai, M. Kawahara, M. Nakagawa, C.J. Kane, P.R. Carroll, R. Dahiya: Ethnic grouprelated differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int.J. Cancer. 20;116 174-181 (2005)
33. P.M. Das, K. Ramachandran, J. Vanwert, L. Ferdinand, G. Gopisetty, I.M. Reis, R. Singal: Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol. Cancer. 5: 28. 28 (2006)
34. A. Bhardwaj, S. Singh, A.P. Singh: MicroRNAbased Cancer Therapeutics: Big Hope from Small RNAs. Mol. Cell Pharmacol. 2 213-219 (2010)
35. A. Bhardwaj, S. Arora, V.K. Prajapati, S. Singh, A.P. Singh: Cancer "stemness"- regulating microRNAs: role, mechanisms and therapeutic potential. Curr. Drug Targets. 14 1175-1184 (2013) DOI: 10.2174/13894501113149990190
36. S.K. Srivastava, S. Arora, S. Singh, A. Bhardwaj, C. Averett, A.P. Singh: MicroRNAs in pancreatic malignancy: progress and promises. Cancer Lett. 347 167-174 (2014) DOI: 10.1016/j.canlet.2014.02.015
37. G.A. Calin, C.M. Croce: MicroRNA signatures in human cancers. Nat. Rev. Cancer. 6 857-866 (2006) DOI: 10.1038/nrc1997
38. S.C. Theodore, J.S. Rhim, T. Turner, C. Yates: MiRNA 26a expression in a novel panel of African American prostate cancer cell lines. Ethn. Dis. 20 S1-100 (2010)
39. S.C. Theodore, M. Davis, F. Zhao, H. Wang, D. Chen, J. Rhim, W. Dean-Colomb, T. Turner, W. Ji, G. Zeng, W. Grizzle, C. Yates: MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget. 5 3512-3525 (2014) DOI: 10.18632/oncotarget.1953
40. D. Hatcher, G. Daniels, I. Osman, P. Lee: Molecular mechanisms involving prostate cancer racial disparity. Am.J. Transl. Res. 20;1 235-248 (2009)
41. B.D. Wang, K. Ceniccola, Q. Yang, R. Andrawis, V. Patel, Y. Ji, J. Rhim, J. Olender, A. Popratiloff, P. Latham, Y. Lai, S.R. Patierno, N.H. Lee: Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. Clin. Cancer Res. 21 4970-4984 (2015) DOI: 10.1158/1078-0432.CCR-14-1566
42. K.E. Gaston, D. Kim, S. Singh, O.H. Ford, III, J.L. Mohler: Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J. Urol. 170 990-993 (2003) DOI: 10.1097/01.ju.0000079761.56154.e5
43. B.D. Wang, Q. Yang, K. Ceniccola, F. Bianco, R. Andrawis, T. Jarrett, H. Frazier, S.R. Patierno, N.H. Lee: Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer DOI: 10.1.155/2013/763569 (2013)
44. T.L. Sreenath, A. Dobi, G. Petrovics, S. Srivastava: Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J. Carcinog. 10: 37. 37-3163 (2011) DOI: 10.4.103/1477-3163.9.1122.
45. M.C. Bosland: The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev. Urol. 7 Suppl 3: S4-S10. S4-S10 (2005)
46. R. Ross, L. Bernstein, H. Judd, R. Hanisch, M. Pike, B. Henderson: Serum testosterone levels in healthy young black and white men. J. Natl. Cancer Inst. 76 45-48 (1986)
47. M.C. Bosland, H. Ford, L. Horton: Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd: SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis. 16 1311-1317 (1995) DOI: 10.1093/carcin/16.6.1311
48. F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, M.G. Kris: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 4885-4892 (2000)
49. F.M. Sirotnak, Y. She, F. Lee, J. Chen, H.I. Scher: Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin. Cancer Res. 8 3870-3876 (2002)
50. F. Gebhardt, K.S. Zanker, B. Brandt: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274 13176-13180 (1999) DOI: 10.1074/jbc.274.19.13176
51. D. Hatcher, G. Daniels, I. Osman, P. Lee: Molecular mechanisms involving prostate cancer racial disparity. Am.J. Transl. Res. 20;1 235-248 (2009)
52. L.G. Di, G. Tortora, F.P. D'Armiento, R.G. De, S. Staibano, R. Autorino, M. D'Armiento, L.M. De, P.S. De, G. Catalano, A.R. Bianco, F. Ciardiello: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8 3438-3444 (2002)
53. P.B. Higgins, J.R. Fernandez, M.I. Goran, B.A. Gower: Early ethnic difference in insulin-like growth factor-1 is associated with African genetic admixture. Pediatr. Res. 58 850-854 (2005) DOI: 10.1203/01.PDR.0000182583.92130.08
54. A.M. De Marzo, E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, C.G. Drake, Y. Nakai, W.B. Isaacs, W.G. Nelson: Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 7 256-269 (2007) DOI: 10.1038/nrc2090
55. A. Strasner, M. Karin: Immune Infiltration and Prostate Cancer. Front Oncol. 5: 128 (2015) DOI: 10.3389/fonc.2015.00128
56. S.K. Deshmukh, S.K. Srivastava, A. Bhardwaj, A.P. Singh, N. Tyagi, S. Marimuthu, D.L. Dyess, Z. Dal, V, J.E. Carter, S. Singh: Resistin and interleukin-6 exhibit raciallydisparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget. 6 11231-11241 (2015) DOI: 10.18632/oncotarget.3591
57. G. Landskron, M. De la Fuente, P. Thuwajit, C. Thuwajit, M.A. Hermoso: Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014: 149185 DOI: 10.1.155/2014/149185.
58. J.A. Eastham, R.A. May, T. Whatley, A. Crow, D.D. Venable, O. Sartor: Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J. Natl. Cancer Inst. 20;90 756-760 (1998)
59. T.A. Wallace, R.L. Prueitt, M. Yi, T.M. Howe, J.W. Gillespie, H.G. Yfantis, R.M. Stephens, N.E. Caporaso, C.A. Loffredo, S. Ambs: Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68 927-936 (2008) DOI: 10.1158/0008-5472.CAN-07-2608
60. M.A. Kinseth, Z. Jia, F. Rahmatpanah, A. Sawyers, M. Sutton, J. Wang-Rodriguez, D. Mercola, K.L. McGuire: Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int.J. Cancer. 134 81-91 (2014) DOI: 10.1002/ijc.28326
61. Z. Culig: Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am.J. Clin. Exp. Urol. 2 231-238 (2014)
62. D.P. Nguyen, J. Li, A.K. Tewari: Inflammation and prostate cancer: the role of interleukin 6 (IL-6) BJU. Int. 113 986-992 (2014) DOI: 10.1111/bju.12452
63. C.L. Coe, G.D. Love, M. Karasawa, N. Kawakami, S. Kitayama, H.R. Markus, R.P. Tracy, C.D. Ryff: Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav. Immun. 25 494-502 (2011) DOI: 10.1016/j.bbi.2010.11.013
64. T.L. Gruenewald, S. Cohen, K.A. Matthews, R. Tracy, T.E. Seeman: Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Soc. Sci. Med. 69 451-459 (2009) DOI: 10.1016/j.socscimed.2009.05.018
65. N. Ranjit, A.V. Diez-Roux, S. Shea, M. Cushman, T. Seeman, S.A. Jackson, H. Ni: Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch. Intern. Med. 167 174-181 (2007) DOI: 10.1001/archinte.167.2.174